For the quarter ending 2025-12-31, ENTA made $18,615K in revenue. -$11,938K in net income. Net profit margin of -64.13%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total revenue | 18,615 | 16,042 | 18,314 | 14,926 |
| Research and development | 20,859 | 25,733 | 27,210 | 28,065 |
| General and administrative | 9,009 | 11,274 | 9,997 | 11,388 |
| Total operating expenses | 29,868 | 37,007 | 37,207 | 39,453 |
| Loss from operations | -11,253 | -20,964 | -18,893 | -24,527 |
| Interest expense | 3,083 | 2,175 | 1,618 | 1,714 |
| Interest and investment income, net | 2,422 | 2,433 | 2,285 | 2,292 |
| Change in fair value of series 1 nonconvertible preferred stock | - | 10 | - | - |
| Total other (expense) income, net | -661 | 278 | 667 | 578 |
| Loss before income taxes | -11,914 | -20,687 | -18,226 | -23,949 |
| Income tax (expense) benefit | 24 | -192 | 29 | -1,305 |
| Net loss | -11,938 | -20,495 | -18,255 | -22,644 |
| Basic | 28,748,000 | -21,355,332 | 21,377,000 | 21,355,000 |
| Earnings per share, basic | -0.42 | -0.965 | -0.85 | -1.06 |
| Earnings per share, diluted | -0.42 | -0.965 | -0.85 | -1.06 |
| Weighted average number of shares outstanding, diluted | 28,748,000 | -21,355,332 | 21,377,000 | 21,355,000 |
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)